Deep Dive: CGRP Therapies: First-Line Status, New Safety Signal

Generated July 2026 · Clinical Deep Dive0 CommentsA practicing clinician’s guide to all 8 FDA-approved CGRP-targeted agents: mechanism, agent selection, safety, and monitoringFor most of their history, CGRP-targeted therapies were treatments of last resort. As of March 2024, that is no longer true, and a lot of practicing clinicians have not caught up. The American Headache Society’s updated position statement now designates CGRP-targeting therapies a first-line option for migraine prevention, explicitly stating that initiation should not require trial and failure of non-specific migraine preventive medication approaches. Headache That single sentence rewrites the referral and prior-authorization logic that has governed this class since erenumab’s 2018 approval, and it means a patient sitting in front of you today with four migraine days a month has a legitimate claim to a CGRP agent before anyone tries topiramate, a beta-blocker, or an SNRI.That expansion is colliding with a safety story that is still being written, and two signals in particular deserve tracking. The first is vascular: a 2025 analysis of the FDA Adverse Event Reporting System found a significant disproportionality signal for Raynaud phenomenon across the CGRP class as a whole (reporting odds ratio 19.12; 95% CI, 15.44–23.69), with individual-agent signals ranging widely and fremanezumab, galcanezumab, and ubrogepant among the highest. SciRep The second is hypertension, which prompted an FDA label update after postmarketing reports, though the real-world data are more reassuring than those case reports alone would suggest: a 2025 systematic review encompassing 75,065 patients across five studies found no significant hypertension signal in normotensive patients, with only a small annual increase in antihypertensive medication use among those with pre-existing hypertension. Cureus Both signals were characterized while CGRP therapies were still reserved largely for patients who had already failed other preventives; the population now eligible under first-line criteria is broader than the one those studies captured. Headache As Shaheen Lakhan, MD, PhD, put it to Medscape, these agents "have not been a universal or magical fix, but they have meaningfully improved outcomes for many patients who previously cycled through nonspecific preventives with poor tolerability." MedscapeThere are now eight FDA-approved CGRP-targeted agents split across two mechanistically distinct subclasses (four monoclonal antibodies and four gepants), with meaningfully different routes, dosing intervals, indications, and interaction profiles. This review works through the mechanism, the full agent roster, the pharmacokinetics that actually change a prescribing decision, a framework for choosing between agents, the safety signals worth tracking, and where the pipeline is heading next: the working knowledge this first-line shift now demands of anyone who prescribes for migraine.FIGURE 1. The CGRP Class at a Glance: Mechanism, Route, and IndicationAgent (brand)Subclass / targetRoute & intervalAcute indicationPreventive indicationErenumab (Aimovig) DailyMedmAb (CGRP receptor)SC, monthlyNoYes (episodic + chronic)Fremanezumab (Ajovy) DailyMedmAb (CGRP ligand)SC, monthly or quarterlyNoYes (episodic + chronic)Galcanezumab (Emgality) DailyMedmAb (CGRP ligand)SC, monthlyNoYes (episodic + chronic); also episodic cluster headacheEptinezumab (Vyepti) DailyMedmAb (CGRP ligand)IV infusion, quarterlyNoYes (episodic + chronic)Ubrogepant (Ubrelvy) DailyMedGepant (oral)Oral, as neededYesNoRimegepant (Nurtec ODT) DailyMedGepant (oral)Oral; as needed for acute use, every other day for preventionYesYes (episodic); only dual-indication agentAtogepant (Qulipta) DailyMedGepant (oral)Oral, once dailyNoYes (episodic + chronic)Zavegepant (Zavzpret) DailyMedGepant (intranasal)Intranasal, as neededYesNoDEEP DIVE:Eight Agents, One Class: Choosing Among CGRP TherapiesMedscape Medical News © 2026 WebMD, LLCSend comments and news tips to news@medscape.net. Cite this: CGRP Therapies Are Now First-Line for Migraine, and So Is a Raynaud Signal Nobody Can Fully Explain - Medscape- July 17, 2026.